Elisabeth Schorb

3.2k total citations
31 papers, 757 citations indexed

About

Elisabeth Schorb is a scholar working on Neurology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Elisabeth Schorb has authored 31 papers receiving a total of 757 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Neurology, 21 papers in Pathology and Forensic Medicine and 18 papers in Genetics. Recurrent topics in Elisabeth Schorb's work include CNS Lymphoma Diagnosis and Treatment (28 papers), Lymphoma Diagnosis and Treatment (21 papers) and Glioma Diagnosis and Treatment (17 papers). Elisabeth Schorb is often cited by papers focused on CNS Lymphoma Diagnosis and Treatment (28 papers), Lymphoma Diagnosis and Treatment (21 papers) and Glioma Diagnosis and Treatment (17 papers). Elisabeth Schorb collaborates with scholars based in Germany, Switzerland and United Kingdom. Elisabeth Schorb's co-authors include Gerald Illerhaus, Benjamin Kasenda, Jürgen Finke, Kristina Fritsch, Gabriele Ihorst, Heidi Fricker, Andrés J.M. Ferreri, Kate Cwynarski, Agnieszka Korfel and Karl Otfried Schwab and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Neurology.

In The Last Decade

Elisabeth Schorb

29 papers receiving 741 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisabeth Schorb Germany 14 537 515 424 80 60 31 757
Elizabeth Kurczynski United States 12 390 0.7× 39 0.1× 452 1.1× 5 0.1× 44 0.7× 17 985
Gila Sellam Switzerland 15 135 0.3× 427 0.8× 129 0.3× 52 0.7× 304 5.1× 32 743
Tadamasa Yasunaga Japan 11 87 0.2× 45 0.1× 56 0.1× 20 0.3× 36 0.6× 27 351
Naoto Fujita Japan 12 74 0.1× 189 0.4× 56 0.1× 15 0.2× 136 2.3× 42 392
Umberto Tirelli Italy 14 175 0.3× 417 0.8× 109 0.3× 4 0.1× 445 7.4× 27 616
Jack van Hoff United States 10 94 0.2× 33 0.1× 79 0.2× 6 0.1× 73 1.2× 21 453
Jan‐Erik Johansson Sweden 12 24 0.0× 123 0.2× 37 0.1× 37 0.5× 121 2.0× 29 456
G. Fraile Spain 11 30 0.1× 109 0.2× 37 0.1× 15 0.2× 51 0.8× 26 403
Eduardo Martín‐Nares Mexico 13 95 0.2× 56 0.1× 57 0.1× 6 0.1× 26 0.4× 43 538
Eren Demirtaş Türkiye 13 75 0.1× 24 0.0× 45 0.1× 15 0.2× 69 1.1× 25 390

Countries citing papers authored by Elisabeth Schorb

Since Specialization
Citations

This map shows the geographic impact of Elisabeth Schorb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Schorb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Schorb more than expected).

Fields of papers citing papers by Elisabeth Schorb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Schorb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Schorb. The network helps show where Elisabeth Schorb may publish in the future.

Co-authorship network of co-authors of Elisabeth Schorb

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Schorb. A scholar is included among the top collaborators of Elisabeth Schorb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Schorb. Elisabeth Schorb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Illerhaus, Gerald, Jeanette K. Doorduijn, Dorothee P. Auer, et al.. (2024). Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up. HemaSphere. 8(6). e89–e89. 5 indexed citations
3.
Wendler, Julia, Christopher P. Fox, Elke Valk, et al.. (2022). Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer. 22(1). 971–971. 3 indexed citations
4.
Montesinos‐Rongen, Manuel, Anna Brunn, Armin Tuchscherer, et al.. (2020). Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics. 22(10). 1300–1307. 13 indexed citations
5.
Schorb, Elisabeth, Benjamin Kasenda, Gabriele Ihorst, et al.. (2020). High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Advances. 4(14). 3378–3381. 27 indexed citations
6.
Schorb, Elisabeth, Jürgen Finke, Gabriele Ihorst, et al.. (2019). Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. BMC Cancer. 19(1). 287–287. 15 indexed citations
7.
Schmitt, Andreas M., Amanda K. Herbrand, Christopher P. Fox, et al.. (2019). Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis. Hematological Oncology. 37(5). 548–557. 51 indexed citations
8.
Hottenrott, Tilman, Elisabeth Schorb, Kristina Fritsch, et al.. (2018). The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis. Journal of Neurology. 265(5). 1106–1114. 13 indexed citations
9.
10.
11.
12.
Kasenda, Benjamin, Gabriele Ihorst, Heidi Fricker, et al.. (2016). Quality of Life in Patients with Primary CNS Lymphoma - a Pooled Analysis from Three Prospective Multicentre Trials. Blood. 128(22). 5385–5385. 1 indexed citations
13.
Korfel, Agnieszka, Elisabeth Schorb, Uwe Schlegel, et al.. (2016). Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL). Clinical Lymphoma Myeloma & Leukemia. 16. S107–S108. 1 indexed citations
14.
Doolittle, Nancy D., Agnieszka Korfel, Elisabeth Schorb, et al.. (2013). Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology. 81(1). 84–92. 105 indexed citations
15.
Schorb, Elisabeth, Benjamin Kasenda, J. Atta, et al.. (2013). Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica. 98(5). 765–770. 65 indexed citations
16.
Kasenda, Benjamin, Petra Thürmann, Hendrik Veelken, et al.. (2012). The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients. Annals of Hematology. 91(8). 1257–1264. 13 indexed citations
17.
Kasenda, Benjamin, Elisabeth Schorb, Kristina Fritsch, Jürgen Finke, & Gerald Illerhaus. (2012). Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma—a long-term follow-up study. Annals of Oncology. 23(10). 2670–2675. 67 indexed citations
18.
Kasenda, Benjamin, Elisabeth Schorb, Kristina Fritsch, et al.. (2012). 18F-FDG PET Is an Independent Outcome Predictor in Primary Central Nervous System Lymphoma. Journal of Nuclear Medicine. 54(2). 184–191. 32 indexed citations
19.
Schwab, Karl Otfried, et al.. (2008). Marked smoking-associated increase of cardiovascular risk in childhood type 1 diabetes. International Journal of Adolescent Medicine and Health. 20(3). 285–292. 25 indexed citations
20.
Schwab, Karl Otfried, Jürgen Doerfer, Andreas Krebs, et al.. (2007). Early atherosclerosis in childhood type 1 diabetes: role of raised systolic blood pressure in the absence of dyslipidaemia. European Journal of Pediatrics. 166(6). 541–548. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Kurczynski Breakdown of academic impact, for papers by Gila Sellam Breakdown of academic impact, for papers by Tadamasa Yasunaga Breakdown of academic impact, for papers by Naoto Fujita Breakdown of academic impact, for papers by Umberto Tirelli Breakdown of academic impact, for papers by Jack van Hoff Breakdown of academic impact, for papers by Jan‐Erik Johansson Breakdown of academic impact, for papers by G. Fraile Breakdown of academic impact, for papers by Eduardo Martín‐Nares Breakdown of academic impact, for papers by Eren Demirtaş
Rankless by CCL
2026